|
US20010031264A1
(en)
|
1996-01-25 |
2001-10-18 |
Andrew Segal |
Vaccine compositions and methods of modulating immune responses
|
|
US7083784B2
(en)
|
2000-12-12 |
2006-08-01 |
Medimmune, Inc. |
Molecules with extended half-lives, compositions and uses thereof
|
|
US20050215472A1
(en)
|
2001-10-23 |
2005-09-29 |
Psma Development Company, Llc |
PSMA formulations and uses thereof
|
|
JP5355839B2
(ja)
|
2001-10-23 |
2013-11-27 |
ピーエスエムエー デベロプメント カンパニー， エル．エル．シー． |
Ｐｓｍａ抗体およびタンパク質マルチマー
|
|
DK1629011T3
(da)
|
2003-05-31 |
2010-05-03 |
Micromet Ag |
Humane anti-humane-DC3-bindingsmolekyler
|
|
CA2654794A1
(en)
|
2006-06-14 |
2007-12-21 |
Imclone Systems Incorporated |
Lyophilized formulations of anti-egfr antibodies
|
|
RU2769948C2
(ru)
|
2007-04-03 |
2022-04-11 |
Эмджен Рисерч (Мьюник) Гмбх |
CD3-Эпсилон-связывающий домен с межвидовой специфичностью
|
|
RS53008B2
(sr)
|
2007-04-03 |
2022-12-30 |
Amgen Res Munich Gmbh |
Interspecijski specifičan cd3-epsilon vezujući domen
|
|
PL2188313T3
(pl)
|
2007-08-21 |
2018-04-30 |
Amgen, Inc. |
Białka wiążące ludzki antygen c-fms
|
|
EP2497783A3
(en)
|
2007-09-26 |
2013-04-17 |
U3 Pharma GmbH |
Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
|
|
DK2352763T4
(da)
|
2008-10-01 |
2022-10-17 |
Amgen Res Munich Gmbh |
Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener
|
|
US20110293619A1
(en)
|
2008-10-01 |
2011-12-01 |
Micromet Ag |
CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY
|
|
RU2636046C2
(ru)
|
2009-01-12 |
2017-11-17 |
Сайтомкс Терапьютикс, Инк |
Композиции модифицированных антител, способы их получения и применения
|
|
TWI653333B
(zh)
|
2010-04-01 |
2019-03-11 |
安進研究（慕尼黑）有限責任公司 |
跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
|
|
US8557961B2
(en)
|
2010-04-02 |
2013-10-15 |
Amunix Operating Inc. |
Alpha 1-antitrypsin compositions and methods of making and using same
|
|
GB201203442D0
(en)
|
2012-02-28 |
2012-04-11 |
Univ Birmingham |
Immunotherapeutic molecules and uses
|
|
MX353382B
(es)
|
2012-03-01 |
2018-01-10 |
Amgen Res Munich Gmbh |
Moleculas de union polipeptido de larga duracion.
|
|
CN110078827A
(zh)
|
2012-04-27 |
2019-08-02 |
西托姆克斯治疗公司 |
结合表皮生长因子受体的可活化的抗体其使用方法
|
|
US9856314B2
(en)
|
2012-06-22 |
2018-01-02 |
Cytomx Therapeutics, Inc. |
Activatable antibodies having non-binding steric moieties and methods of using the same
|
|
AU2013289883B2
(en)
*
|
2012-07-13 |
2018-11-01 |
Zymeworks Bc Inc. |
Bispecific asymmetric heterodimers comprising anti-CD3 constructs
|
|
US9562110B2
(en)
|
2012-11-21 |
2017-02-07 |
Wuhan Yzy Biopharma Co., Ltd. |
Bispecific antibody
|
|
CN105283201B
(zh)
|
2013-03-14 |
2019-08-02 |
斯克利普斯研究所 |
靶向剂抗体偶联物及其用途
|
|
PL2970449T3
(pl)
|
2013-03-15 |
2020-04-30 |
Amgen Research (Munich) Gmbh |
Jednołańcuchowe cząsteczki wiążące zawierające N-końcowy ABP
|
|
US9562073B2
(en)
|
2014-01-31 |
2017-02-07 |
Cytomx Therapeutics, Inc. |
Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
|
|
CA2955947A1
(en)
|
2014-07-25 |
2016-01-28 |
Cytomx Therapeutics, Inc. |
Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
|
|
EP3174901B1
(en)
|
2014-07-31 |
2019-06-26 |
Amgen Research (Munich) GmbH |
Optimized cross-species specific bispecific single chain antibody constructs
|
|
MX2017003847A
(es)
|
2014-09-25 |
2017-12-15 |
Amgen Inc |
Proteinas biespecificas activables por proteasas.
|
|
MX2017006016A
(es)
|
2014-11-11 |
2017-06-19 |
Amunix Operating Inc |
Composiciones conjugadas de xten direccionadas y metodos para producir las mismas.
|
|
MA41374A
(fr)
|
2015-01-20 |
2017-11-28 |
Cytomx Therapeutics Inc |
Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
|
|
EP3288981A1
(en)
|
2015-05-01 |
2018-03-07 |
Genentech, Inc. |
Masked anti-cd3 antibodies and methods of use
|
|
BR112017023862A2
(pt)
|
2015-05-04 |
2018-07-17 |
Cytomx Therapeutics Inc |
anticorpos anti-cd71, anticorpos anti-cd71 ativáveis, e métodos de uso destes
|
|
US9708412B2
(en)
|
2015-05-21 |
2017-07-18 |
Harpoon Therapeutics, Inc. |
Trispecific binding proteins and methods of use
|
|
EP3322715B1
(en)
|
2015-07-14 |
2023-10-18 |
BioNTech SE |
Peptide mimotopes of the cd3 t-cell co-receptor epsilon chain and uses thereof
|
|
JOP20160154B1
(ar)
*
|
2015-07-31 |
2021-08-17 |
Regeneron Pharma |
أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
|
|
IL319047A
(en)
|
2015-08-28 |
2025-04-01 |
Amunix Operating Inc |
Chimeric polypeptide composition and methods for its preparation and use
|
|
EA201891753A1
(ru)
|
2016-02-03 |
2019-01-31 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкции антител к psma и cd3, вовлекающие т-клетки
|
|
CN109071667A
(zh)
|
2016-03-08 |
2018-12-21 |
马弗里克治疗公司 |
可诱导性结合蛋白和使用方法
|
|
JP7015244B2
(ja)
|
2016-03-22 |
2022-02-02 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
プロテアーゼ活性化ｔ細胞二重特異性分子
|
|
US12297266B2
(en)
|
2016-04-18 |
2025-05-13 |
Celldex Therapeutics, Inc. |
Agonistic antibodies that bind human CD40 and uses thereof
|
|
WO2017201493A1
(en)
|
2016-05-20 |
2017-11-23 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment cd3 binding proteins
|
|
EP3493844A4
(en)
|
2016-05-20 |
2021-03-24 |
Harpoon Therapeutics Inc. |
SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN
|
|
MY200695A
(en)
|
2016-11-03 |
2024-01-11 |
Bristol Myers Squibb Co |
Activatable anti-ctla-4 antibodies and uses thereof
|
|
WO2018098356A1
(en)
|
2016-11-23 |
2018-05-31 |
Harpoon Therapeutics, Inc. |
Psma targeting trispecific proteins and methods of use
|
|
US11690919B2
(en)
|
2017-01-17 |
2023-07-04 |
The Texas A&M University System |
Endolysosomal targeting conjugates for improved delivery of cargo molecules to the endolysosomal compartment of target cells
|
|
WO2018209304A1
(en)
*
|
2017-05-12 |
2018-11-15 |
Harpoon Therapeutics, Inc. |
Msln targeting trispecific proteins and methods of use
|
|
CN111356700A
(zh)
|
2017-09-08 |
2020-06-30 |
马弗里克治疗公司 |
受约束的条件性活化的结合蛋白
|
|
EP3694885A1
(en)
|
2017-10-14 |
2020-08-19 |
CytomX Therapeutics, Inc. |
Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
|
|
EP3710480A4
(en)
|
2017-11-17 |
2021-12-15 |
Nanjing Legend Biotech Co., Ltd. |
SINGLE-DOMAIN ANTIBODIES AND VARIANTS OF THEM DIRECTED AGAINST PD-L1
|
|
AU2018393111B2
(en)
*
|
2017-12-21 |
2025-07-10 |
Amunix Pharmaceuticals, Inc. |
Release segments and binding compositions comprising same
|
|
JP2021518603A
(ja)
|
2018-03-20 |
2021-08-02 |
シートムエックス セラピューティクス，インコーポレイテッド |
哺乳動物対象における活性化可能抗体種の定量薬理学モデリングのためのシステムおよび方法
|
|
BR112020023330A2
(pt)
|
2018-05-14 |
2021-04-20 |
Harpoon Therapeutics, Inc. |
porção de ligação para ativação condicional de moléculas de imunoglobulina
|
|
WO2019222278A1
(en)
*
|
2018-05-14 |
2019-11-21 |
Harpoon Therapeutics, Inc. |
Dual binding moiety
|
|
US20210309756A1
(en)
|
2018-08-09 |
2021-10-07 |
Maverick Therapeutics, Inc. |
Coexpression and purification method of conditionally activated binding proteins
|
|
WO2020058762A1
(en)
|
2018-09-20 |
2020-03-26 |
Tikcro Technologies Ltd |
Antibodies specific to ctla-4 and uses thereof
|
|
US20220002370A1
(en)
|
2018-09-27 |
2022-01-06 |
Xilio Development, Inc. |
Masked cytokine polypeptides
|
|
CA3120327A1
(en)
|
2018-12-06 |
2020-06-11 |
Cytomx Therapeutics, Inc. |
Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
|
|
GB2583560A
(en)
|
2018-12-11 |
2020-11-04 |
Admirx Inc |
Fusion protein constructs for complement associated disease
|
|
EP3911371A4
(en)
*
|
2019-01-18 |
2023-04-26 |
University of Southern California |
METHODS AND COMPOSITIONS FOR IMPROVING THE SAFETY AND EFFICACY OF CELL THERAPY
|
|
JP2022524337A
(ja)
|
2019-03-05 |
2022-05-02 |
武田薬品工業株式会社 |
腫瘍抗原を標的とするｆｃ領域及び部分を含有する条件的に活性化された結合タンパク質
|
|
EP4592313A3
(en)
|
2019-03-05 |
2025-11-19 |
Takeda Pharmaceutical Company Limited |
Constrained conditionally activated binding proteins
|
|
CN113811546B
(zh)
*
|
2019-05-07 |
2025-03-11 |
免疫里森公司 |
前体三特异性抗体构建体及其使用方法
|
|
JP2022535924A
(ja)
|
2019-06-06 |
2022-08-10 |
ジャナックス セラピューティクス，インク． |
腫瘍活性化ｔ細胞エンゲージャーに関する組成物および方法
|
|
CA3143519A1
(en)
|
2019-06-26 |
2020-12-30 |
Volker Schellenberger |
Cd3 antigen binding fragments and compositions comprising same
|
|
EP4631977A3
(en)
|
2020-08-11 |
2025-12-10 |
Janux Therapeutics, Inc. |
Cleavable linker compositions and methods
|
|
US20240043565A1
(en)
|
2020-10-15 |
2024-02-08 |
Janux Therapeutics, Inc. |
Antibodies targeting psma and cd3 and uses thereof
|
|
WO2022098909A1
(en)
*
|
2020-11-06 |
2022-05-12 |
Harpoon Therapeutics, Inc. |
Epcam targeting trispecific protein for treatment of cancer
|
|
JP2023552462A
(ja)
|
2020-12-08 |
2023-12-15 |
ジャナックス セラピューティクス，インク． |
半減期延長組成物および方法
|
|
US20240043536A1
(en)
|
2020-12-08 |
2024-02-08 |
Janux Therapeutics, Inc. |
Peptide compositions and methods for anti-cd3 binding domains
|
|
AU2021396172A1
(en)
|
2020-12-09 |
2023-07-06 |
Janux Therapeutics, Inc. |
Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
|